Cargando…

Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study

OBJECTIVES: Studies regarding the epidemiology of systemic lupus erythematosus (SLE) are lacking in Argentina. Our purpose was to estimate the incidence and prevalence of SLE in a university hospital-based health management organisation in Buenos Aires (HIMCP). METHODS: For incidence calculation, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Scolnik, M, Marin, J, Valeiras, S M, Marchese, M F, Talani, A S, Avellaneda, N L, Etchepare, A, Etchepare, P, Plou, M S, Soriano, E R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213830/
https://www.ncbi.nlm.nih.gov/pubmed/25379189
http://dx.doi.org/10.1136/lupus-2014-000021
_version_ 1782341874428674048
author Scolnik, M
Marin, J
Valeiras, S M
Marchese, M F
Talani, A S
Avellaneda, N L
Etchepare, A
Etchepare, P
Plou, M S
Soriano, E R
author_facet Scolnik, M
Marin, J
Valeiras, S M
Marchese, M F
Talani, A S
Avellaneda, N L
Etchepare, A
Etchepare, P
Plou, M S
Soriano, E R
author_sort Scolnik, M
collection PubMed
description OBJECTIVES: Studies regarding the epidemiology of systemic lupus erythematosus (SLE) are lacking in Argentina. Our purpose was to estimate the incidence and prevalence of SLE in a university hospital-based health management organisation in Buenos Aires (HIMCP). METHODS: For incidence calculation, the population at risk included all adult members of the HIMCP, with continuous affiliation for at least 1 year from January 1998 to January 2009. Each person was followed until he/she voluntarily left the HIMCP, death or finalisation of the study. Multiple methods for case finding were used to ensure complete ascertainment: (a) patients with problem SLE, undifferentiated autoimmune disease or mixed connective tissue disease in the Computer-based Patient Record System, (b) patients with positive antinuclear antibody test, anti-Sm antibodies and/or anti-dsDNA antibodies in the laboratory database and (c) patients who consumed hydroxichloroquine, chloroquine, azathioprine, cyclophosphamide, mycophenolate, cyclosporine or rituximab, from the administrative HIMCP drugs database. Medical records of all patients found were reviewed, and only patients fulfilling ACR criteria for SLE were included. Global and gender incidence rate (IR) was calculated. Prevalence was estimated on 1 January 2009, and the denominator population was the number of active members >18 years at that date (n=127 959). RESULTS: In the study period, 68 patients developed SLE. The observed IR (per 100 000 person-years, (CI 95%)) was 6.3 (4.9 to 7.7) for total population; 8.9 (CI 6.6 to 11.2) for women and 2.6 (1.2 to 3.9) for men. On 1 January 2009, 75 prevalent cases were identified. Prevalence rates (cases per 100 000 habitants, (CI 95%)) were 58.6 (46.1 to 73.5) for total population; 83.2 (63.9 to 106.4) for women and 23 (CI 11.9 to 40.1) for men. CONCLUSIONS: SLE incidence and prevalence rates in Argentina are in agreement with those of other studies from different parts of the world.
format Online
Article
Text
id pubmed-4213830
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-42138302014-11-06 Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study Scolnik, M Marin, J Valeiras, S M Marchese, M F Talani, A S Avellaneda, N L Etchepare, A Etchepare, P Plou, M S Soriano, E R Lupus Sci Med Epidemiology and Outcomes OBJECTIVES: Studies regarding the epidemiology of systemic lupus erythematosus (SLE) are lacking in Argentina. Our purpose was to estimate the incidence and prevalence of SLE in a university hospital-based health management organisation in Buenos Aires (HIMCP). METHODS: For incidence calculation, the population at risk included all adult members of the HIMCP, with continuous affiliation for at least 1 year from January 1998 to January 2009. Each person was followed until he/she voluntarily left the HIMCP, death or finalisation of the study. Multiple methods for case finding were used to ensure complete ascertainment: (a) patients with problem SLE, undifferentiated autoimmune disease or mixed connective tissue disease in the Computer-based Patient Record System, (b) patients with positive antinuclear antibody test, anti-Sm antibodies and/or anti-dsDNA antibodies in the laboratory database and (c) patients who consumed hydroxichloroquine, chloroquine, azathioprine, cyclophosphamide, mycophenolate, cyclosporine or rituximab, from the administrative HIMCP drugs database. Medical records of all patients found were reviewed, and only patients fulfilling ACR criteria for SLE were included. Global and gender incidence rate (IR) was calculated. Prevalence was estimated on 1 January 2009, and the denominator population was the number of active members >18 years at that date (n=127 959). RESULTS: In the study period, 68 patients developed SLE. The observed IR (per 100 000 person-years, (CI 95%)) was 6.3 (4.9 to 7.7) for total population; 8.9 (CI 6.6 to 11.2) for women and 2.6 (1.2 to 3.9) for men. On 1 January 2009, 75 prevalent cases were identified. Prevalence rates (cases per 100 000 habitants, (CI 95%)) were 58.6 (46.1 to 73.5) for total population; 83.2 (63.9 to 106.4) for women and 23 (CI 11.9 to 40.1) for men. CONCLUSIONS: SLE incidence and prevalence rates in Argentina are in agreement with those of other studies from different parts of the world. BMJ Publishing Group 2014-06-05 /pmc/articles/PMC4213830/ /pubmed/25379189 http://dx.doi.org/10.1136/lupus-2014-000021 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Epidemiology and Outcomes
Scolnik, M
Marin, J
Valeiras, S M
Marchese, M F
Talani, A S
Avellaneda, N L
Etchepare, A
Etchepare, P
Plou, M S
Soriano, E R
Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study
title Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study
title_full Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study
title_fullStr Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study
title_full_unstemmed Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study
title_short Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study
title_sort incidence and prevalence of lupus in buenos aires, argentina: a 11-year health management organisation-based study
topic Epidemiology and Outcomes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213830/
https://www.ncbi.nlm.nih.gov/pubmed/25379189
http://dx.doi.org/10.1136/lupus-2014-000021
work_keys_str_mv AT scolnikm incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy
AT marinj incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy
AT valeirassm incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy
AT marchesemf incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy
AT talanias incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy
AT avellanedanl incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy
AT etcheparea incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy
AT etcheparep incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy
AT ploums incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy
AT sorianoer incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy